Vertex Pharmaceuticals

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market with its Trikafta franchise, which generates billions in annual revenue and treats the underlying cause of the disease rather than just symptoms. The company is expanding into pain management, gene editing, kidney disease, and other serious conditions, building a diversified pipeline beyond its CF stronghold. It appeals to growth and healthcare investors seeking a profitable, cash-rich biotech with a proven commercial track...

Threads